European Commission grants approval of Ogsiveo
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
PEKK is a high-performance polymer family used in aerospace and other demanding markets
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
Subscribe To Our Newsletter & Stay Updated